Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Corbus Pharmaceuticals ( (CRBP) ).
On December 12, 2025, Corbus Pharmaceuticals Holdings, Inc. announced that board member Alan Holmer notified the company of his decision to retire and will resign from its Board of Directors effective December 31, 2025. The company stated that Holmer’s departure was not due to any disagreement over its operations, policies, or practices, suggesting an orderly governance transition with no underlying operational or strategic dispute signaled to stakeholders.
The most recent analyst rating on (CRBP) stock is a Buy with a $53.00 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.
Spark’s Take on CRBP Stock
According to Spark, TipRanks’ AI Analyst, CRBP is a Neutral.
Corbus Pharmaceuticals’ overall stock score is driven by severe financial challenges, including no recent revenue and high net losses, which significantly weigh down its score. However, technical indicators suggest some short-term positive momentum. The promising Phase 1 trial results provide a potential catalyst in the biotechnology field, offering some positive outlook despite the current financial difficulties.
To see Spark’s full report on CRBP stock, click here.
More about Corbus Pharmaceuticals
Average Trading Volume: 456,870
Technical Sentiment Signal: Sell
Current Market Cap: $152M
See more data about CRBP stock on TipRanks’ Stock Analysis page.